Supplementary Material

Case Report: Improvement in refractory functional seizures, depression, and quality of life with ketamine-assisted therapy

Elena Argento PhD1,2\*, Egiroh Omene MD, FRCPC3†, Alexandria H Jaeger MSc1†, Angela Kertes PhD, C.Psych3,4, Kaitlyn A Mitchell MSc, RN3, Candace Necyk PhD1, Paul Thielking MD5, Evan Cole Lewis MD, FRCPC3

1Numinus Wellness Inc., Vancouver, BC, Canada

2British Columbia Centre on Substance Use, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada

3Neurology Centre of Toronto by Numinus, Toronto, ON, Canada

4North Toronto Psychology, Toronto, ON, Canada

5Numinus Wellness, Draper, UT, USA

†These authors contributed equally to this work

**\* Correspondence:**  
Elena Argento, PhD, MPH  
[bccsu-ea@bccsu.ubc.ca](mailto:bccsu-ea@bccsu.ubc.ca)

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Session** | **Week** | | **WSAS** | | **QIDS** | **Warwick Edinburgh** | **Sublingual Dose (mg)** | **Intranasal Dose (mg)** | **Total Dose (mg)** |
| **Treatment 1** | Week 1 | | 34 | | 16 | 49 | 100 | 30 | 130 |
| **Treatment 2** | Week 3 | | 20 | | 11 | 54 | 150 | 45 | 195 |
| **Treatment 3** | Week 4 | | 9.5 | | 17 | 46 | 200 | 60 | 260 |
| **Maintenance 1** | Week 5 | | 8.5 | | 10 | 64 | 100 | 30 | 130 |
| **Maintenance 2** | Week 6 | | 3 | | 13 | 66 | 100 | 30 | 130 |
| **Maintenance 3** | Week 7 | | 3 | | 8 | 58 | 100 | 30 | 130 |
| **Maintenance 4** | Week 8 | | 30 | | 19 | 32 | 150 | 30 | 180 |
| **Maintenance 5** | Week 10 | | 15 | | 17 | 37 | 150 | 30 | 180 |
| **Maintenance 6** | Week 12 | | 15 | | 18.5 | 29.5 | 150 | 30 | 180 |
| **Interval Update** | Week 13 | | 3.5 | | 9 | 45 | 0 | 0 | 0 |
| **Maintenance 7** | Week 15 | | 5 | | 12.5 | 42 | 150 | 30 | 180 |
| **Maintenance 8** | Week 16 | | 12 | | 18 | 38 | 150 | 0 | 150 |
| **Interval Update** | Week 17 | | 11 | | 11 | 49 | 0 | 0 | 0 |
| **Maintenance 9** | | Week 19 | 5 | 7 | | 50 | 150 | 0 | 150 |
| **Maintenance 10** | | Week 23 | \*n/a | 8 | | 54 | 150 | 0 | 150 |

**Supplementary Table 1:** Psychosocial Tests and Dosing during Treatment and Maintenance Sessions. Psychosocial measures administered at treatment, maintenance sessions and interval updates. Quick Inventory of Depressive Symptomatology (QIDS); Work and Social Adjustment Score (WSAS), Warwick Edinburgh. Dosing breakdown in milligrams (mg) by route of administration of ketamine for all sessions. Treatment session dosing was administered as a stack of sublingual (SL) and intranasal (IN) routes, administered in series with the IN as a supplement dispensed at 20 minutes. Maintenance session dosing was administered as a combination of SL and IN routes in parallel. \*n/a as measure was not administered.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Session** | **Week** | **PHQ-9** | **GAD-7** | **PCL5** |
| **Maintenance 1** | Week 5 | 3 | 5 | 11 |
| **Maintenance 4** | Week 8 | 16 | 13 | 29 |
| **Interval Update** | Week 13 | 4.5 | 4.5 | 6 |
| **Maintenance 7** | Week 15 | \*n/a | 8 | 14 |
| **Maintenance 8** | Week 16 | 9 | 7 | 13.5 |
| **Interval Update** | Week 17 | 8 | 5 | 26 |
| **Maintenance 9** | Week 19 | 5 | 11 | 14 |
| **Maintenance 10** | Week 23 | 2 | 3 | 12 |

**Supplementary Table 2:** Psychosocial measures administered at maintenance sessions and interval updates. Personal Health Questionnaire-9 (PHQ-9); Generalized Anxiety Disorder-7 (GAD-7); PTSD Checklist DSM 5 (PCL-5). \*n/a as measure was not administered.